Dr. James Li is a partner of KPCB China. He joins in Oct 2009 to focus on fund’s life science practice. His main investment interests are in the space of bio-pharmaceuticals, vaccines, diagnostics and personalized medicine enabling tools, research services, medical devices and other life science opportunities in China.

James is also a member of Kleiner Perkins Caufield & Byers Pandemic Fund in which his interests are in the areas of the management of emerging infectious disease, specifically in bird flu and swine flu’s rapid diagnosis, prevention and treatment.

Prior to joining KPCB, James spent over 15 years with Merck Co. & Inc. where he held leadership positions with increasing responsibilities in clinical research, regulatory affairs, new product development and franchise management, both in the US and Asia Pacific/China. During his tenure, he was instrumental in obtaining regulatory approvals of Merck vaccines accross Asia Pacific Region when the Vaccine Division started operations in the region, successfully built the foundations of Merck’s medical operations in China and drove the success of Merck’s largest product franchise in Asia.

James received his Medical Degree from Shanghai Medical University, completing an internship in Internal Medicine and a rotation in Oncology, followed by a Master of Science degree in Microbiology from the University of Montana.

James is currently involved with the following companies: BioCryst, GenScript, Kang Hui, Nexus Diagnostics, and Novavax.

E-mail: jamesl@kpcb.com